參 考 文 獻
[1] H. Sung, J. Ferlay, R. L. Siegel, M. Laversanne, I. Soerjomataram, A. Jemal, and
F. Bray, “Global cancer statistics 2020: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries,” CA: a cancer journal for clinicians, vol. 71, no. 3, pp. 209–249, 2021.
[2] S. Kunte, J. Abraham, and A. J. Montero, “Novel her2–targeted therapies for her2–
positive metastatic breast cancer,” Cancer, vol. 126, no. 19, pp. 4278–4288, 2020.
[3] M. F. Press, J. A. Seoane, C. Curtis, E. Quinaux, R. Guzman, G. Sauter, W. Eiermann, J. R. Mackey, N. Robert, T. Pienkowski, et al., “Assessment of erbb2/her2 status in
her2-equivocal breast cancers by fish and 2013/2014 asco-cap guidelines,” JAMA
oncology, vol. 5, no. 3, pp. 366–375, 2019.
[4] T. Hilal and E. H. Romond, “ERBB2 (HER2) testing in breast cancer,” JAMA,
vol. 315, no. 12, pp. 1280–1281, 2016.
[5] A. Emde, W. J. Köstler, Y. Yarden, and Association of Radiotherapy and Oncology
of the Mediterranean arEa (AROME), “Therapeutic strategies and mechanisms of
tumorigenesis of HER2-overexpressing breast cancer,” Crit. Rev. Oncol. Hematol.,
vol. 84 Suppl 1, pp. e49–57, Dec. 2012.
[6] D. Jelovac and L. A. Emens, “HER2-directed therapy for metastatic breast cancer,”
Oncology (Williston Park), vol. 27, pp. 166–175, Mar. 2013.
[7] A. M. Gown, L. C. Goldstein, T. S. Barry, S. J. Kussick, P. L. Kandalaft, P. M. Kim, and C. C. Tse, “High concordance between immunohistochemistry and fluorescence
in situ hybridization testing for HER2 status in breast cancer requires a normalized
IHC scoring system,” Mod. Pathol., vol. 21, pp. 1271–1277, Oct. 2008.
[8] Z.-H. Liu, K. Wang, D.-Y. Lin, J. Xu, J. Chen, X.-Y. Long, Y. Ge, X.-L. Luo, K.-P.Zhang, Y.-H. Liu, et al., “Impact of the updated 2018 asco/cap guidelines on her2
fish testing in invasive breast cancer: a retrospective study of her2 fish results of
2233 cases,” Breast cancer research and treatment, vol. 175, no. 1, pp. 51–57, 2019.
[9] S. Agersborg, C. Mixon, T. Nguyen, S. Aithal, S. Sudarsanam, F. Blocker, L. Weiss, R. Gasparini, S. Jiang, W. Chen, G. Hess, and M. Albitar, “Immunohistochemistry
and alternative FISH testing in breast cancer with HER2 equivocal amplification,”
Breast Cancer Res. Treat., vol. 170, pp. 321–328, July 2018.
[10] M. Troxell, R. K. Sibley, R. B. West, G. R. Bean, and K. H. Allison, “HER2 dual
in situ hybridization: Correlations and cautions,” Arch. Pathol. Lab. Med., vol. 144,
pp. 1525–1534, Dec. 2020.
[11] M. Edelweiss, A. P. M. Sebastiao, H. Oen, M. Kracun, R. Serrette, and D. S. Ross, “Her2 assessment by bright-field dual in situ hybridization in cell blocks of recurrent and metastatic breast carcinoma,” Cancer cytopathology, vol. 127, no. 11, pp. 684–
690, 2019.
[12] P. Pati, A. Foncubierta-Rodríguez, O. Goksel, and M. Gabrani, “Reducing annotation effort in digital pathology: A co-representation learning framework for classification
tasks,” Medical image analysis, vol. 67, p. 101859, 2021.
[13] R. Mormont, P. Geurts, and R. Marée, “Multi-task pre-training of deep neural networks for digital pathology,” IEEE journal of biomedical and health informatics,
vol. 25, no. 2, pp. 412–421, 2020.
[14] G. Litjens, T. Kooi, B. E. Bejnordi, A. A. A. Setio, F. Ciompi, M. Ghafoorian, J. A. Van Der Laak, B. Van Ginneken, and C. I. Sánchez, “A survey on deep learning in
medical image analysis,” Medical image analysis, vol. 42, pp. 60–88, 2017.
[15] F. Zakrzewski, W. de Back, M. Weigert, T. Wenke, S. Zeugner, R. Mantey, C. Sperling, K. Friedrich, I. Roeder, D. Aust, et al., “Automated detection of the her2 gene amplification status in fluorescence in situ hybridization images for the diagnostics
of cancer tissues,” Scientific reports, vol. 9, no. 1, pp. 1–12, 2019.
[16] K. Bera, K. A. Schalper, D. L. Rimm, V. Velcheti, and A. Madabhushi, “Artificial
intelligence in digital pathology—new tools for diagnosis and precision oncology,”
Nature reviews Clinical oncology, vol. 16, no. 11, pp. 703–715, 2019.
[17] K.-H. Yu, A. L. Beam, and I. S. Kohane, “Artificial intelligence in healthcare,” Nature biomedical engineering, vol. 2, no. 10, pp. 719–731, 2018.
[18] C.-W. Wang, S.-C. Huang, Y.-C. Lee, Y.-J. Shen, S.-I. Meng, and J. L. Gaol, “Deep learning for bone marrow cell detection and classification on whole-slide images,” Medical Image Analysis, vol. 75, p. 102270, 2022.
[19] J. Redmon and A. Farhadi, “Yolo9000: better, faster, stronger,” in Proceedings of the IEEE conference on computer vision and pattern recognition, pp. 7263–7271,
2017.
[20] X. Zhang, X. Zhu, K. Tang, Y. Zhao, Z. Lu, and Q. Feng, “Ddtnet: A dense dual-task network for tumor-infiltrating lymphocyte detection and segmentation in histopathological images of breast cancer,” Medical Image Analysis, vol. 78, p. 102415, 2022.
[21] M.-A. Khalil, Y.-C. Lee, H.-C. Lien, Y.-M. Jeng, and C.-W. Wang, “Fast segmentation of metastatic foci in h&e whole-slide images for breast cancer diagnosis,” Diagnostics, vol. 12, no. 4, p. 990, 2022.
[22] Y.-J. Lin, T.-K. Chao, M.-A. Khalil, Y.-C. Lee, D.-Z. Hong, J.-J. Wu, and C.-W.
Wang, “Deep learning fast screening approach on cytological whole slides for thyroid
cancer diagnosis,” Cancers, vol. 13, no. 15, p. 3891, 2021.
[23] C.-W. Wang, Y.-A. Liou, Y.-J. Lin, C.-C. Chang, P.-H. Chu, Y.-C. Lee, C.-H. Wang, and T.-K. Chao, “Artificial intelligence-assisted fast screening cervical high grade
squamous intraepithelial lesion and squamous cell carcinoma diagnosis and treatment planning,” Scientific Reports, vol. 11, no. 1, pp. 1–14, 2021.
[24] T. Falk, D. Mai, R. Bensch, Ö. Çiçek, A. Abdulkadir, Y. Marrakchi, A. Böhm,
J. Deubner, Z. Jäckel, K. Seiwald, et al., “U-net: deep learning for cell counting,
detection, and morphometry,” Nature methods, vol. 16, no. 1, pp. 67–70, 2019.
[25] C.-W. Wang, K.-Y. Lin, Y.-J. Lin, M.-A. Khalil, K.-L. Chu, and T.-K. Chao, “A soft label deep learning to assist breast cancer target therapy and thyroid cancer diagnosis,” Cancers, vol. 14, no. 21, p. 5312, 2022.
[26] S.-H. Lee, W. Erber, A. Porwit, M. Tomonaga, L. Peterson, and I. C. S. I. Hematology, “Icsh guidelines for the standardization of bone marrow specimens and reports,” International journal of laboratory hematology, vol. 30, no. 5, pp. 349–364, 2008.
[27] C.-W. Wang, Y.-C. Lee, C.-C. Chang, Y.-J. Lin, Y.-A. Liou, P.-C. Hsu, C.-C. Chang, A.-K.-O. Sai, C.-H. Wang, and T.-K. Chao, “A weakly supervised deep learning
method for guiding ovarian cancer treatment and identifying an effective biomarker,”
Cancers, vol. 14, no. 7, p. 1651, 2022
[28] C.-W. Wang, C.-C. Chang, Y.-C. Lee, Y.-J. Lin, S.-C. Lo, P.-C. Hsu, Y.-A. Liou,
C.-H. Wang, and T.-K. Chao, “Weakly supervised deep learning for prediction of
treatment effectiveness on ovarian cancer from histopathology images,” Computerized Medical Imaging and Graphics, vol. 99, p. 102093, 2022.
[29] L.-C. Chen, Y. Zhu, G. Papandreou, F. Schroff, and H. Adam, “Encoder-decoder with atrous separable convolution for semantic image segmentation,” in Proceedings of
the European conference on computer vision (ECCV), pp. 801–818, 2018.
[30] C.-W. Wang, S.-C. Huang, M.-A. Khalil, D.-Z. Hong, S.-I. Meng, and Y.-C. Lee,
“CW-NET for multitype cell detection and classification in bone marrow examination and mitotic figure examination,” Bioinformatics, vol. 39, 05 2023. btad344.
[31] C.-W. Wang, M.-A. Khalil, Y.-J. Lin, Y.-C. Lee, and T.-K. Chao, “Detection of erbb2 and cen17 signals in fluorescent in situ hybridization and dual in situ hybridization
for guiding breast cancer her2 target therapy,” Artificial Intelligence in Medicine,
vol. 141, p. 102568, 2023.
[32] Z. Cai and N. Vasconcelos, “Cascade r-cnn: Delving into high quality object detection,” in Proceedings of the IEEE conference on computer vision and pattern
recognition, pp. 6154–6162, 2018.
[33] E. Upschulte, S. Harmeling, K. Amunts, and T. Dickscheid, “Contour proposal networks for biomedical instance segmentation,” Medical Image Analysis, p. 102371,
2022.
[34] L. Ke, Y.-W. Tai, and C.-K. Tang, “Deep occlusion-aware instance segmentation with overlapping bilayers,” in Proceedings of the IEEE/CVF Conference on Computer
Vision and Pattern Recognition (CVPR), pp. 4019–4028, June 2021.
[35] X. Wang, R. Zhang, T. Kong, L. Li, and C. Shen, “Solov2: Dynamic and fast instance segmentation,” Advances in Neural information processing systems, vol. 33,
pp. 17721–17732, 2020.
[36] K. He, G. Gkioxari, P. Dollár, and R. Girshick, “Mask r-cnn,” in Proceedings of the IEEE international conference on computer vision, pp. 2961–2969, 2017.
[37] Z. Liu, Y. Lin, Y. Cao, H. Hu, Y. Wei, Z. Zhang, S. Lin, and B. Guo, “Swin transformer: Hierarchical vision transformer using shifted windows,” in Proceedings of the IEEE/CVF International Conference on Computer Vision, pp. 10012–10022,
2021.
[38] G. C. Cawley and N. L. Talbot, “On over-fitting in model selection and subsequent selection bias in performance evaluation,” The Journal of Machine Learning Research, vol. 11, pp. 2079–2107, 2010.
[39] C.-W. Wang, C.-C. Chang, Y.-C. Lee, Y.-J. Lin, S.-C. Lo, P.-C. Hsu, Y.-A. Liou,
C.-H. Wang, and T.-K. Chao, “Weakly supervised deep learning for prediction of
treatment effectiveness on ovarian cancer from histopathology images,” Computerized Medical Imaging and Graphics, vol. 99, p. 102093, 2022.
[40] A. G. Howard, M. Zhu, B. Chen, D. Kalenichenko, W. Wang, T. Weyand, M. Andreetto, and H. Adam, “Mobilenets: Efficient convolutional neural networks for mobile vision applications,” arXiv preprint arXiv:1704.04861, 2017.
[41] K. He, X. Zhang, S. Ren, and J. Sun, “Deep residual learning for image recognition,”in Proceedings of the IEEE conference on computer vision and pattern recognition, pp. 770–778, 2016.
[42] F. Chollet, “Xception: Deep learning with depthwise separable convolutions,” in
Proceedings of the IEEE conference on computer vision and pattern recognition,
pp. 1251–1258, 2017.
[43] C. Szegedy, S. Ioffe, V. Vanhoucke, and A. A. Alemi, “Inception-v4, inception-resnet and the impact of residual connections on learning,” in Thirty-first AAAI conference
on artificial intelligence, 2017.
[44] V. Badrinarayanan, A. Kendall, and R. Cipolla, “Segnet: A deep convolutional
encoder-decoder architecture for image segmentation,” IEEE transactions on pattern analysis and machine intelligence, vol. 39, no. 12, pp. 2481–2495, 2017.
[45] E. Shelhamer, J. Long, and T. Darrell, “Fully convolutional networks for semantic segmentation,” IEEE transactions on pattern analysis and machine intelligence,vol. 39, no. 4, pp. 640–651, 2017.
[46] C.-W. Wang, S.-M. Ka, and A. Chen, “Robust image registration of biological microscopic images,” Scientific reports, vol. 4, no. 1, pp. 1–12, 2014.
[47] C.-W. Wang and H.-C. Chen, “Improved image alignment method in application to
x-ray images and biological images,” Bioinformatics, vol. 29, no. 15, pp. 1879–1887,
2013.
[48] S. Xie, R. Girshick, P. Dollár, Z. Tu, and K. He, “Aggregated residual transformations for deep neural networks,” in Proceedings of the IEEE conference on computer vision
and pattern recognition, pp. 1492–1500, 2017.
[49] S. Ahn, J. W. Woo, K. Lee, and S. Y. Park, “Her2 status in breast cancer: changes in guidelines and complicating factors for interpretation,” Journal of pathology and translational medicine, vol. 54, no. 1, pp. 34–44, 2020.
[50] F. Meric-Bernstam, A. M. Johnson, E. E. I. Dumbrava, K. Raghav, K. Balaji,
M. Bhatt, R. K. Murthy, J. Rodon, and S. A. Piha-Paul, “Advances in her2-targeted
therapy: novel agents and opportunities beyond breast and gastric cancer,” Clinical
Cancer Research, vol. 25, no. 7, pp. 2033–2041, 2019.
[51] N. Mohan, J. Jiang, M. Dokmanovic, and W. J. Wu, “Trastuzumab-mediated cardiotoxicity: current understanding, challenges, and frontiers,” Antibody therapeutics, vol. 1, no. 1, pp. 13–17, 2018.
[52] E. J. A. Bowles, R. Wellman, H. S. Feigelson, A. A. Onitilo, A. N. Freedman, T. Delate, L. A. Allen, L. Nekhlyudov, K. A. Goddard, R. L. Davis, et al., “Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study,” Journal of the National Cancer Institute, vol. 104, no. 17,pp. 1293–1305, 2012.
[53] X. Zhu and S. Verma, “Targeted therapy in her2-positive metastatic breast cancer: a review of the literature,” Curr. Oncol., vol. 22, pp. S19–28, Mar. 2015.